- ►heartcarefound.org [PDF] R Kahn, J Buse, E Ferrannini, M Stern - Diabetologia, 2005 - Springer Page 1. Diabetologia (2005) 48: 1684–1699 DOI 10.1007/s00125-005-1876-2 REVIEW R. Kahn . J. Buse . E.
Ferrannini . M. Stern The metabolic syndrome: time for a critical appraisal Joint statement from the
American Diabetes Association and the European Association for the Study of Diabetes ... Cited by 1188 - Related articles - BL Direct - All 52 versions
- ►hopkinsmedicine.org [PDF] SE Kahn, SM Haffner, MA Heise, WH Herman, … - New England Journal …, 2006 - content.nejm.org From the Veterans Affairs Puget Sound Health Care System and University of Washington, Seattle
(SEK); University of Texas Health Science Center at San An tonio, San Antonio (SMH); GlaxoSmith
Kline, King of Prussia, PA (MAH, ... Cited by 781 - Related articles - BL Direct - All 30 versions
JD Browning, LS Szczepaniak, R Dobbins, P … - Hepatology, 2004 - interscience.wiley.com Despite the increasing prevalence of nonalcoholic fatty liver disease (NAFLD), its pathogenesis and
clinical significance remain poorly defined. In this study, we examined and compared the
distribution of hepatic ... Cited by 532 - Related articles - All 3 versions
- ►homestead.com [PDF] JB Dixon, PE O'Brien, J Playfair, L Chapman, LM … - Jama, 2008 - Am Med Assoc You are seeing this message because your Web browser does not support basic Web standards. Find out
more about why this message is appearing and what you can do to make your experience on this site
better. ... Context Observational ... Cited by 194 - Related articles - BL Direct - All 10 versions
- ►jhsph.edu [PDF] CM Larsen, M Faulenbach, A Vaag, A … - The New England …, 2007 - nejm.highwire.org Methods In this double-blind, parallel-group trial involving 70 patients with type 2 diabetes, we
randomly assigned 34 patients to receive 100 mg of anakinra (a recombinant human
interleukin-1–receptor ... Cited by 144 - Related articles - BL Direct - All 12 versions
MA Nauck, S Duran, D Kim, D Johns, J Northrup, A … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority trial was to compare
the safety and efficacy of exenatide (an incretin mimetic) with that of biphasic insulin aspart.
Materials and methods Patients on ... Cited by 134 - Related articles - BL Direct - All 4 versions
- ►annals.org [PDF] B Zinman, BJ Hoogwerf, S Duran Garcia, … - Annals of internal …, 2007 - Am Coll Physicians Background: Exenatide therapy is effective in combination with metformin or sulfonylureas for
treating type 2 diabetes. Thiazo- lidinediones (TZDs) also are commonly used, but the efficacy of
exenatide with a TZD has not been ... Cited by 121 - Related articles - BL Direct - All 5 versions
J McMillan-Price, P Petocz, F Atkinson, K O' … - Archives of Internal …, 2006 - archinte.highwire.org Methods A total of 129 overweight or obese young adults (body mass index, 25 [calculated as weight
in kilograms divided by the square of height in meters]) were assigned to 1 of 4 reduced-fat,
high-fiber diets for 12 weeks. ... Cited by 116 - Related articles - BL Direct - All 4 versions
M Adiels, MR Taskinen, C Packard, MJ Caslake, A … - Diabetologia, 2006 - Springer Page 1. Diabetologia (2006) 49: 755–765 DOI 10.1007/s00125-005-0125-z ARTICLE M. Adiels .
M.-R. Taskinen . C. Packard . MJ Caslake . A. Soro-Paavonen . J. Westerbacka . S. Vehkavaara .
A. Häkkinen . S.-O. Olofsson . H. Yki-Järvinen . J. Borén ... Cited by 116 - Related articles - BL Direct - All 5 versions
- ►endojournals.org BL Wajchenberg - Endocrine reviews, 2007 - Endocrine Soc There is a progressive deterioration in ß-cell function and mass in type 2 diabetics. It was found
that islet function was about 50% of normal at the time of diagnosis, and a reduction in ß-cell
mass of about 60% was shown at ... Cited by 105 - Related articles - BL Direct - All 7 versions
